GSK (FKA GLAXOSMITHKLINE INC.)

Registrant on federal lobbying filings · filed 2025 to 2026

$0 Income reported

1 Clients represented

6 Filings counted

0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. It also reported $7,350,000 of in-house lobbying expenses, which is what a registrant files when it lobbies for itself. 1 filing on this record was restated by a later amendment and is left out of every total here. Everything on this page is grouped by the registrant's LDA id (16293), not by name.

Clients 1

GSK (FKA GLAXOSMITHKLINE INC.) $7,350,000 6 filings

Lobbyists named 2

CARA WALTHER 1 filing · through 2026 Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017
JASEY CARDENAS 1 filing · through 2026 Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016

A lobbyist who previously held a covered government position must disclose it. We flag the ones whose name resolves to a member of Congress and link the ones still in our roster. The revolving door collects them across every firm.

Reported by year 2 years

2026 $2,530,000 2 filings
2025 $4,820,000 4 filings

Issues lobbied 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 7

Centers For Medicare and Medicaid Services (CMS) 6
Health & Human Services, Dept of (HHS) 6
HOUSE OF REPRESENTATIVES 6
Office of Management & Budget (OMB) 6
Patent & Trademark Office (PTO) 6
SENATE 6
U.S. Trade Representative (USTR) 6

Recent filings 7 total

Q2 report

GSK (FKA GLAXOSMITHKLINE INC.)

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $890,000 expenses · posted Jul 16, 2026

View → Q1 report

GSK (FKA GLAXOSMITHKLINE INC.)

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $1,640,000 expenses · posted Apr 20, 2026

View → Q4 report

GSK (FKA GLAXOSMITHKLINE INC.)

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $810,000 expenses · posted Jan 20, 2026

View → Q3 report

GSK (FKA GLAXOSMITHKLINE INC.)

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $1,700,000 expenses · posted Oct 20, 2025

View → Q2 report

GSK (FKA GLAXOSMITHKLINE INC.)

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $1,510,000 expenses · posted Jul 21, 2025

View → Q1 amendment

GSK (FKA GLAXOSMITHKLINE INC.)

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $800,000 expenses · posted May 6, 2025

View → Q1 report

GSK (FKA GLAXOSMITHKLINE INC.) Amended

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $800,000 expenses · posted Apr 21, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.